



Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2072627 C 2003/12/16

(11)(21) **2 072 627**

(12) **BREVET CANADIEN  
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1991/09/10  
(87) Date publication PCT/PCT Publication Date: 1992/03/19  
(45) Date de délivrance/Issue Date: 2003/12/16  
(85) Entrée phase nationale/National Entry: 1992/04/30  
(86) N° demande PCT/PCT Application No.: US 1991/006532  
(87) N° publication PCT/PCT Publication No.: 1992/004050  
(30) Priorité/Priority: 1990/09/10 (579,834) US

(51) Cl.Int.<sup>5</sup>/Int.Cl.<sup>5</sup> C12N 7/01, A61K 39/245  
(72) Inventeur/Inventor:  
ROIZMAN, BERNARD, US  
(73) Propriétaire/Owner:  
ARCH DEVELOPMENT CORP., US  
(74) Agent: FINLAYSON & SINGLEHURST

(54) Titre : VACCINS A BASE D'HERPESVIRUS ET METHODES  
(54) Title: RECOMBINANT HERPES SIMPLEX VIRUSES VACCINES AND METHODS

(57) **Abrégé/Abstract:**

A virus is disclosed which is rendered avirulent by prevention of expression of an active product of a gene which is designated as  $\gamma_1$  34.5, which maps in the inverted repeats flanking the long unique sequence of herpes simplex virus DNA, and which is not essential for viral growth in cell culture. Viruses from which the gene was deleted or which carried stop codons are totally avirulent on intracerebral inoculation of mice.



RECOMBINANT HERPES SIMPLEX VIRUSES

VACCINES AND METHODS

2072627

ABSTRACT

A virus is disclosed which is rendered avirulent by prevention of expression of an active product of a gene which is designated as  $\gamma_1$ 34.5, which maps in the inverted repeats flanking the long unique sequence of herpes simplex virus DNA, and which is not essential for viral growth in cell culture. Viruses from which the gene was deleted or which carried stop codons are totally avirulent on intracerebral inoculation of mice.

- 1 -

2072627

RECOMBINANT HERPES SIMPLEX VIRUSES  
VACCINES AND METHODS

BACKGROUND

5           The present invention relates in general to  
recombinant virus strains, live viral vaccines, methods  
for making the strains and vaccines, and methods for  
immunizing a host against a virus. More specifically,  
the present invention relates to recombinant herpesvirus  
10 strains, live viral vaccines incorporating such strains,  
methods for making such strains and vaccines, and methods  
for immunizing a human host against herpes simplex virus  
using the vaccines wherein a vaccinal viral DNA does not  
encode an active ICP34.5 gene product, such as a  
15 herpesvirus having a deletion or a stop codon in reading  
frame within a coding region in all copies of the ICP34.5  
gene.

          Viruses may cause infected cells to produce  
specific proteins. These proteins interact with each  
20 other and with cellular proteins and with viral nucleic  
acids to cause viral progeny to be made, to destroy the  
infected cell and to spread infection to previously  
noninfected cells. Some of these proteins also stimulate  
a host immune response, which may permit the viruses  
25 encoding them to be useful as a component of a viral  
vaccine.

          Herpes simplex virus (HSV) is a relatively  
common human pathogen which can cause fatal disease in  
the young or immunosuppressed.

30           There are two distinct serotypes, herpes  
simplex virus type 1 ("HSV-1") and herpes simplex virus  
type 2 ("HSV-2"), respectively associated with fever  
blisters and genital lesions. HSV-1 and HSV-2 are

- 2 -

related immunologically, but most of their proteins carry distinguishing characteristics which allow them to be differentiated. See, Morse et al, J. Virol., 26(2), 389 - 410 (1978), the disclosure of which may be referred to for further details.

HSV is characterized by the ability to establish latent infections in the central nervous system ("CNS") of its host, specifically the neural ganglia [Stevens et al, J. Exp. Medicine, 133, 19 - 38 (1971)]. This tropism for the CNS may result in encephalitis [Whitley, Virology, 2nd ed., Fields et al, eds., Raven Press, New York, 1843 - 1887 (1990)].

Several regions of the HSV genome may relate to viral neurovirulence. These regions include those containing the thymidine kinase gene [Field et al, J. Hygiene, 81, 267 - 277 (1978)] the DNA polymerase gene [Larder et al, J. Gen. Virol., 67, 2501 - 2506 (1986)], sequences within the internal repeats (Thompson et al, J. Virol., 55(2), 504 - 508 (1985); Meignier et al, J. Infect. Diseases, 158(3), 602 - 614 (1988) and sequences between map units ("mu") 0.25 and 0.53 [Thompson et al, J. Virol., 58, 203 - 211 (1986)]. A neural-specific, latency-associated transcript (LAT) in the long repeats may also be of interest, although there is no demonstrated function for the transcript thereof.

A virus strain useful in a vaccine against HSV-1 and HSV-2 may be avirulent, stable (i.e, does not revert to the virulent state), provide demonstrated immunity to massive challenges of wild type strains of both HSV-1 and HSV-2, have low pathogenicity and be incapable of transforming host cells. It may be desirable for the vaccinal virus to disappear, or capable of reactivation, after immunization of a host, but in some cases it may be desirable for the virus to remain in a latent form in the host. This is best accomplished by

2072627

- 3 -

a virus which contains only a small alteration in the genomic structure, thereby preserving the ability to replicate well outside the host while maintaining normal expression of immunity-inducing viral components.

5 Therefore, it is useful to obtain a stable, non-transforming live viral vaccine which either does not establish latent infections or which cannot be reactivated from a latent state, and which is effective against a herpes simplex virus.

#### 10 SUMMARY OF THE INVENTION

A herpes simplex virus (HSV-1 or HSV-2) genome consisting essentially of an otherwise virulent herpes simplex virus which is avirulent for lacking only an ICP34.5 gene encoding an active gene product is provided  
15 according to the present invention. The herpes simplex virus may include an ICP34.5 gene having a stop codon in reading frame between a first and a last codon of a coding sequence of the ICP34.5 gene, and in particular may have a stop codon at a BstEII site in the ICP34.5  
20 gene of HSV-1(F), such as the site in a presently-preferred herpes simplex virus designated R4009 (ATCC VR2278). Alternatively, the herpes simplex virus according to the present invention may include an ICP34.5 gene having a deletion mutation, more particularly, an  
25 ICP34.5 gene lacking a portion of a coding sequence between BstEII and StuI sites in HSV-1(F), which portion may be 1000 base pairs in length, such as in a herpes simplex virus according to the present invention which is designated R3616 (ATCC VR2280).

30 A vaccine including a herpes simplex virus genome is also provided according to the present invention. The genome consists essentially of a herpes simplex virus (HSV-1 or HSV-2) which is avirulent only

2072627

- 4 -

for lacking an ICP34.5 gene encoding an active gene product, and is accompanied by a pharmaceutically acceptable diluent, adjuvant or carrier. In the vaccine, the herpes simplex virus may include an ICP34.5 gene having a stop codon in reading frame between a first and a last codon of a coding sequence of the ICP34.5 gene, particularly a stop codon at a BstEII site in the ICP34.5 gene of HSV-1(F), as in presently-preferred virus R4009 (ATCC VR2278). Alternatively, the herpes simplex virus in the vaccine may include an ICP34.5 gene having a deletion mutation, in particular a deletion of a portion of a coding sequence between BstEII and StuI sites in HSV-1(F), which deletion may be 1000 base pairs in length as in herpes simplex virus designated R3616 (ATCC VR2280).

A method for immunizing a human host against a herpes simplex virus according to the present invention includes a step of inoculating the host with an immunity-inducing dose of a vaccine including a herpes simplex virus genome consisting essentially of an otherwise virulent herpes simplex virus (HSV-1 or HSV-2) which is avirulent only for lacking an ICP34.5 gene encoding an active gene product, and a pharmaceutically acceptable diluent, adjuvant or carrier. The herpes simplex virus may include an ICP34.5 gene having a stop codon in reading frame between a first and a last codon of a coding sequence of the ICP34.5 gene, in particular a stop codon at a BstEII site in the ICP34.5 gene of HSV-1(F), such as is present in presently-preferred virus R4009 (ATCC VR2278). Alternatively, the herpes simplex virus may include an ICP34.5 gene comprising deletion mutation, in particular an ICP34.5 gene which lacks a portion, which may be 1000 base pairs in length, of a coding sequence between BstEII and StuI sites in HSV-1(F), such as in virus R3616 (ATCC VR2280).

2072627

- 5 -

5 A method for preparing a herpes simplex virus (HSV-1 or HSV-2) vaccine according to the present invention includes the steps of preventing transcription of an active product from an ICP34.5 gene an otherwise substantially intact herpes simplex vaccine virus, and combining said vaccine virus with a pharmaceutically acceptable carrier.

10 In the method for preparing a herpes simplex virus (HSV-1 or HSV-2) vaccine, the preventing step may include a step of deleting a portion of said ICP34.5 gene, and the deleting step may include the step of removing a coding sequence which may be 1000 base pairs in length between BstEII and StuI sites in HSV-1(F).  
15 Alternatively, the preventing step may include a step of inserting a stop codon in reading frame between a first and a last codon of a coding sequence of said ICP34.5 gene, and more particularly may include a step of introducing a stop codon at a BstEII site in the ICP34.5 gene of HSV-1(F).

20 BRIEF DESCRIPTION OF THE FIGURES

25 FIG. 1 illustrates a nucleotide sequence for a region of the genome which includes a gene encoding ICP34.5 in HSV-1 strain F (SEQ ID NO:1) showing differences at corresponding positions in the sequences of 17syn+, MGH-10 and CVG-2;

30 FIG. 2 illustrates deduced amino acid sequences encoded by the nucleotide sequences for the gene for ICP34.5 in HSV-1 strains F (SEQ ID NO:2) and 17syn+ (SEQ ID NO:3) showing differences at corresponding positions in the sequences of MGH-10 and CVG-2 as illustrated in FIG. 1;

FIG. 3 is a schematic representation of nucleotide sequences in HSV-1(F) and recombinant viruses

2072627

- 6 -

R3410, R3615 and R3976;

FIG. 4 is a photograph of autoradiographic images and a photograph of stained electrophoretic gels;

5 FIG. 5 is a schematic representation of the genome of wild-type HSV-1 strain F and of recombinant viruses derived from it according to the present invention;

10 FIG. 6 is a photographic reproduction of an autoradiographic image of electrophoretically-separated digests of plasmid, viral and mutant viral DNA; and

FIG. 7 is a photographic reproduction of an autoradiographic image in the right panel, and a photograph of a stained gel in the left panel, both being depictions of denaturing gel electrophoresis of cell  
15 lysates.

#### DETAILED DESCRIPTION

The structure of HSV DNA is described in the literature. See, e.g., Wadsworth et al., J. Virol., 15(6), 1487-1497 (1979); Hayward et al., Proc. Nat. Acad. Sci. (USA), 72(11), 4243-4247 (1975); and Morse et al., J. Virol., 26(2), 389-410 (1978). Each of the HSV-1 and HSV-2 genomes consists of two, covalently-linked components, designated L and S. Each component consists of unique sequences ( $U_L$  for the L component,  $U_S$  for the S component) flanked by inverted repeats. The inverted repeats flanking the L components are designated ab and b'a'. The inverted repeats of the S components are designated as a'c' and ca.

30 In the HSV-1 genome, the long unique sequence is flanked by 9 Kbp inverted repeats designated as ab and b'a', respectively. A terminal 500 bp a sequence acts as a promoter characteristic of "late" or " $\gamma$ " HSV genes such as the  $\gamma_{134.5}$  gene (referred to herein as the ICP34.5

2072627

- 7 -

gene, i.e., as the gene encoding infected cell protein 34.5) the coding sequences of which, located in the adjacent b sequences, specify a protein of 263 amino acids with an apparent molecular weight of 44,000 [Chou et al., J. Virol., 57, 629 (1986); Ackermann et al., J. Virol., 58, 843 (1986) and Chou et al., J. Virol., 64, 1014 (1990)]. The protein contains 3 to 10 repeats of the amino acid sequence Ala-Thr-Pro [Chou et al., J. Virol., 57, 629 (1986); Ackermann et al., J. Virol., 58, 843 (1986) and Chou et al., J. Virol., 64, 1014 (1990)].

The ICP34.5 gene lacks a canonical TATAA box, and the a sequence, its 5' transcribed non-coding domain, is very GC rich, contains numerous repeats and lacks the features characteristic of HSV promoters [Mocarski et al., Proc. Nat' l. Acad. Sci. (USA), 78, 7047 (1981); Mocarski et al., Cell, 31, 89 (1982) and Chou et al., Cell, 41, 80 (1985)]. The a sequence contains the signals and the site of cleavage of the unit length DNA molecule from newly synthesized head to tail concatemers of viral DNA [Mocarski et al., Cell, 31, 89 (1982); Chou et al., Cell, 41, 803 (1985); Deiss et al., J. Virol., 59, 605 (1986); Varmuza et al., Cell, 41, 793 (1985) and Vlazny et al., Proc. Nat' l. Acad. Sci. (USA), 79, 1423 (1982)]. Specifically, the cleavage occurs within a direct repeat which flanks the a sequence [Mocarski et al., Cell, 31, 89 (1982)]. The transcription of the  $\gamma_{134.5}$  gene is initiated in this repeat [Chou et al., J. Virol., 57, 629 (1986)].

As described in Centifanto-Fitzgerald et al., J. Exp. Med., 155, 475-489 (1982), the right terminus of the L component of HSV DNA contains genes the mutation of which leads to loss of neurovirulence as well as the inability to cause lesions in the cornea. These genes are reported to map approximately between 0.70 and 0.83, but their exact location was not identified before the

2072627

- 8 -

present invention.

Poffenberger et al., Proc. Natl. Acad. Sci. (USA), 80, 2690-2694 (1983), and Poffenberger et al., J. Virol., 53, 587-595 (1985), reports that the internal inverted repeats (b'a'a'c') are not essential for the growth of HSV-1 in cell culture. Specifically, a recombinant HSV-1 virus (designated I358, ATCC VR2122) is described in which a portion of the unique sequence at the right end of the L component as well as most of the inverted repeats at the junction between the L and S components in a prototype arrangement is replaced by a small DNA sequence derived from the HindIII O fragment, normally located in the left end of the L component, and the thymidine kinase (TK) gene. The deletion of approximately 13 Kbp of HSV-1 DNA from the inverted repeats of the L and S components in I358 indicates that this virus, or a derivative of this virus, may serve as a vector of HSV DNA or foreign DNA inasmuch as additional DNA sequences may be inserted without affecting the packaging of the genome.

I358 itself is not suitable as a vector primarily because of the duplication of the HindIII O sequences. Because the HindIII O sequences at the novel junction between the L and S component are direct repeats of the sequences contained in the HindIII O fragment at its natural locations, the sequences between the HindIII O repeats spontaneously delete, and defective genomes accumulate in infected cells and culture. However, defective genomes do not contain all viral genes. They require wild type genomes as "helpers." Because they compete for viral and cellular factors, they "interfere," i.e., they reduce the yield of standard genomes. Moreover, even if the I358 genome were to be reconstructed so as to remove the HindIII O sequences duplicated at the novel L-S component junction, it is not

- 9 -

clear whether genes responsible for neurovirulence of the virus are deleted.

Another method used to identify the functions associated with the long unique region is deletion analysis. Meignier et al, J. Infect. Dis., 158, 602 - 614 (1988) reports the removal of 14.5 Kb of DNA spanning the internal repeats of HSV-1. The resulting gap is reported to be filled with DNA from the unique short region of HSV-2, including the glycoproteins gD, gG and gI. The resulting virus, designated R7017, is reported to show an almost 10,000-fold reduction in neurovirulence upon intracranial injection (Meignier et al, J. Infect. Dis., 158(3), 602 - 614 (1988)]. This virus and related constructions are also disclosed in Roizman, U.S. Patent No. 4,859,587.

In or around the long unique region, an intertypic recombinant (HSV-1 X HSV-2) designated RE6, is reported to be over one million times less virulent than either of its parents in Thompson et al, Virology, 131, 171 - 179 (1983). This virus is reported to contain sequences from both HSV-1 (67%) and HSV-2 (33%), of which the latter is reported to contribute the internal and terminal repeats of the long unique region [Thompson et al, Virology, 131, 171 - 179 (1983)]. RE6 is reported to be distinguishable from other non-virulent intertypic recombinants tested in that it grew normally at the physiologic host temperature (38.5°C.). The mutation of RE6 is reported to be rescued to 0.71 mu to 0.83 mu [Thompson et al, Virology, 131, 180 - 192 (1983)]. However, the use of gel-purified fragments in marker rescue experiments, as opposed to the use of cloned DNA, creates the possibility that results may be due to

2072627

- 10 -

contaminating DNA fragments or UV-induced mutations. The use of cloned HSV-1 fragments are reported to show the region including the mutation to be involved with neurovirulence, implicating a specific site at 0.72 mu [Thompson et al., J. Virol., 55(2), 504-508 (1985)]. The region is reported to be narrowed to include only 0.79 mu to 0.82 mu [Javier et al., J. Virol., 61(6), 1978-1984, (1987)], 0.81 to 0.83 [Taha et al., J. Gen. Virology, 70, 705-716 (1989)], and to a 1.6 Kb fragment mapping between 0.82 mu to 0.832 mu [Thompson et al., Virology, 172, 435-450 (1989)].

Javier et al., J. Virol., 65, 1978 (1987) and Thompson et al., Virology, 172, 435 (1989) report that an HSV-1 X HSV-2 recombinant virus consisting largely of HSV-1 DNA but with HSV-2 sequences located at one terminus of the L component is avirulent, and that virulence is restored by rescue of the HSV-2 sequences with the homologous HSV-1 fragment. Taha et al., J. Gen. Virol., 70, 705 (1989) and Taha et al., J. Gen. Virol., 70, 3073 (1989) describe a spontaneous deletion mutant lacking 1.5 Kbp at both ends of the long component of a HSV-2 strain.

A number of genes lie in or around the long unique region of the genome, including the gene for ICP34.5, genes for the immediate early proteins  $\alpha$ -0,  $\alpha$ -4,  $\alpha$ -27, and the sequences giving rise to LAT. The smallest rescuing fragment used by Thompson et al., Virology, 172, 435-450 (1989) is in the region which includes the ICP34.5 gene identified by Chou et al., J. Virol., 57, 629 (1986)]. However, it is reported that the virus strain from which the rescuing fragment was derived does not contain an open reading frame in this region [Perry et al., J. Gen. Virol., 69, 2831-2846 (1988)]. It is also reported that the rescuing strain does not have the open reading frame, but that three other virus strains do

2072627

- 11 -

contain an open reading frame with significant homology to a sequence, suggesting the existence of a genuine gene [Chou et al., J. Virol., 64, 1014 (1990)]. An epitope from the  $\alpha$ -4 polypeptide is reported to be inserted in ICP34.5 and to be useful for precipitating the resulting hybrid protein from infected cells [Chou et al., J. Virol., 64, 1014 (1990)].

Centifanto-Fitzgerald et al., J. Exp. Med., 155, 475 (1982) reports the transfer, by means of a DNA fragment, of a virulence marker from a virulent to an avirulent strain of HSV-1.

Because of heterogeneity in the parent virus population, the loss of virulence has not heretofore been unambiguously related to a specific deletion although a particular recombinant obtained by marker rescue may be more virulent than the corresponding deletion mutant. A specific gene or gene product has not heretofore been unambiguously identified at the mutated locus and no gene has been specifically linked to a virulence phenotype.

It is generally the case that the smaller the deletion, the more likely it is that the virus will multiply in a host while retaining its antigenic properties. The main immune response to HSV-2 and HSV-1 is directed against surface proteins of the virus. The surface proteins of the virus are viral glycoproteins inserted into the virion envelope and into the plasma membrane of infected cells. Currently at least 7 viral glycoproteins are known to be specified by HSV-1 and HSV-2. These are glycoproteins B, C, and H mapping in the L component and glycoproteins D, E, I and G mapping in close proximity to each other in the S component. Of these glycoprotein genes, glycoprotein D mapping in the S component and, to a smaller extent, glycoproteins B and C mapping in the L component induce neutralizing antibody and may induce immunity. The strongest neutralizing

2072627

- 12 -

antibody may be induced by glycoprotein D. This glycoprotein, even by itself, induces some protection in experimental animal systems. Thus, it is desirable that a potential HSV vaccine virus retain antigenic properties.

It is also desirable that a potential HSV vaccine not contain transforming domains. Transforming domains are defined as those which confer upon recipient cells the ability to establish tumors on transplantation in experimental animals. The transforming regions in HSV-2 genome are mapped in the L component of HSV-2 DNA. The corresponding sequences of HSV-1 genome do not immortalize or confer malignant transforming properties to cells. The DNA fragment carrying the genes for glycoprotein D and G of HSV-2 does not contain sequences known to be able to transform cells in culture.

TK viruses (i.e. viruses lacking a TK gene) have a reduced capacity to establish latent infections in experimental animals. The parent virus of 1358 [designated HSV-1(F) $\Delta$ 305, described in Poffenberger et al., Proc. Nat'l. Acad. Sci. (USA), 80, 2690-2694 (1983) and Poffenberger et al., J. Virol., 53, 587-595 (1985), and deposited on August 14, 1990 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland under the accession number VR2279] does not establish latency in experimental animals and it is thus reasonable to expect that the derivatives of 1358 lacking the TK gene would also fail to establish latency. TK viruses, although having reduced capacity to establish latency, may not confer protection.

#### EXAMPLE 1

##### CLONING AND SEQUENCING OF HSV-1 STRAINS

To establish the extent of variability of the open reading frame that encodes ICP34.5, the nucleotide

- 13 -

2072627

sequences of three HSV-1 strains passaged a limited number of times outside a human host were compared.

The isolation and properties of HSV-1(F) are described in Ejercito et al., J. Gen. Virol., 2, 357-364 (1968). HSV-1(MGH-10) is isolated from a case of HSV encephalitis [Hammer et al., J. Infect. Dis., 141, 436-440 (1980)] an isolate obtained from a patient in a pediatric intensive care unit at Cleveland General Hospital [Linnemann et al., Lancet, i, 964-966 (1978)]. Both viruses were passaged only once since they were received, and no more than three times since their isolation from the human hosts. The construction and structure of recombinant virus R3615 is reported elsewhere [Ackermann et al., J. Virol., 58, 843-850 (1986)]. Transfection of the viral and plasmid DNAs on rabbit skin cells and selection of the recombinant viruses under bromodeoxyuridine on human 143 thymidine kinase-negative cells were done as described in Post et al., Cell, 25, 227-232 (1981).

McGeoch et al., J. Gen. Virol., 69, 1531-1574 (1988) and Perry et al., J. Gen. Virol., 67, 2365-2380 (1981) report on the complete nucleotide sequence of HSV-1 strain 17syn+ [HSV-1(17)syn+], noting that in that strain the open reading frame ascribed to ICP34.5 is thoroughly disrupted. HSV-1(F) differs from HSV-1(17)syn+ in several characteristics. HSV-1(F) was isolated from a recurrent facial vesicle [Ejercito et al., J. Gen. Virol., 2, 357-364 (1968)] and passaged a maximum of four times in cells in culture. HSV-1(F) retains the temperature sensitivity characteristic of many HSV-1 isolates passaged a limited number of times in cells in culture. HSV-1(17)syn+, reported in 1973 [Brown et al., J. Gen. Virol., 18, 329-346 (1973)], is described as the progeny of a plaque-purified virus. The passage history of HSV-1(17)syn+ has not been described, but it

2072627

- 14 -

apparently is a multipassage laboratory strain. It may be used as the parental (temperature-resistant) strain for generation of temperature-sensitive mutants.

5 Viral DNAs were prepared from virions that accumulated in the cytoplasm of infected VERO cells as previously described [Kieff et al., J. Virol., 8, 125-132 (1971)]. The BamHI SP junction fragments containing the domain of the gene that specified ICP34.5 were cloned in pUC18 plasmids [Vieira et al., Gene, 19, 259-268 (1982)]  
10 by using HSV-1(F) sequences as probes in colony blot hybridization. Further subclonings were done as necessary to facilitate sequencing of different regions of the gene. The sequencing was done in part by using the dideoxy-chain termination method [Sanger et al.,  
15 Proc. Nat'l Acad. Sci. (USA), 74, 5463-5467 (1977)] and in part by using a Sequences DNA-sequencing kit (United States Biochemical Corp., Cleveland, Ohio) and [ $\alpha$ -<sup>32</sup>P]dATP (Dupont-NEN Research Products, Boston, Massachusetts). Various oligonucleotide primers used in sequencing were  
20 synthesized in an Applied biosystems (Foster City, California) 380D DNA synthesizer. Reactions using dGTP and dITP as substrates in chain elongation and termination as supplied by kit were used to resolve regions of sequences of high G + C content.

25 The nucleotide sequences of the 5'-transcribed noncoding and coding domains of the gene that specifies ICP34.5 in HSV-1(F), HSV-1(MGH-10), HSV-1(CVG-2) along with the reported sequence of HSV-1(17)syn+ [McGeoch et al., J. Gen. Virol., 69, 1531-1574 (1988) and Perry et  
30 al., 69, 2831-2846 (1988)] are shown in FIG. 1.

A comparison of the nucleotide sequences of HSV-1 strains F (SEQ ID NO:1), 17syn+, MGH-10, and CVG-2 in the region of the gene for ICP34.5 is shown in FIG. 1, and the predicted open reading frames for ICP34.5 in  
35 strains F (SEQ ID NO:2) and 17syn+ (SEQ ID NO:2) showing

5 differences at corresponding positions in the sequences  
of MGH-10 and CVG-2 is in FIG. 2. Unless otherwise  
indicated by a new base (insert of A, C, G or T), a new  
amino acid (three-letter code), or the absence of a base  
or amino acid (-), the sequences for strains HSV-  
1(17)syn+, HSV-1(MGH-10), and HSV-1(CVG-2) were identical  
to the sequence for HSV-1(F). An asterisk indicates  
initiation of a repeat sequence of nine nucleotides or  
three amino acids. Direct repeat 1 ("DR1") designates  
10 the 20-base-pair repeat sequence flanking the  $\alpha$  sequence.  
Sequences upstream of direct repeat 1 are contained  
within the  $\alpha$  sequence. The number at end of each line  
indicates the relative position from nucleotide 1 in FIG.  
1 or from amino acid 1 in FIG. 2. The initiation and  
15 termination codons for the HSV-1(F) sequence are  
underlined.

The RNA transcribed across the domain of the  
gene that specific ICP34.5 is initiated within DR1 of the  
 $\alpha$  sequence [Chou et al., J. Virol., 57, 629-637 (1986)].  
20 Methionine codon 1 in all HSV strains is 90 nucleotides  
downstream from DR1, and, in three strains, 17syn+, MGH-  
10, and CVG-2, this sequence is identical in length to  
that of the F strain and differs from it in only one  
nucleotide.

25 The differences among the strains within the  
domain of the gene are as follows. The 5'-noncoding  
domain of the gene that specifies ICP34.5 includes most  
of the  $\alpha$  sequence. The  $\alpha$  sequences of 17syn+, MGH-10 and  
CVG-2 contain a dinucleotide insert and vary in the  
30 nucleotide sequence in the UB domain of the  $\alpha$  sequence.  
Whereas both F and 17 syn+ contain four Arg residues at  
amino acids 3 to 6, strains MGH-10 and CVG-2 contain the  
insert GCC, and encode five Arg residues at that  
position. MGH-10 lacks 21 nucleotides corresponding to  
35 the at positions 46 to 52 of the F strain amino acid

2072627

- 16 -

sequence (SEQ ID NO:2) amino acids (Ala-Pro-Pro-Pro-Pro-Pro-Ala) present in all other strains. The strain 17syn+ sequence contains two additional nucleotides not present in other strains. HSV-1(F) and all other strains contain the sequence GCCCCCGGTCCCCA at nucleotide positions 437 to 450 in the F strain nucleotide sequence (SEQ ID NO:1), whereas the reported sequence for strain 17syn+ has a cytosine between positions 432 and 433 and between positions 449 and 450 of the F strain nucleotide sequence (SEQ ID NO:1) and a substitution of a guanosine at position 445 of the F strain nucleotide sequence (SEQ ID NO:1) to form the sequence GCCCCCGGGCCCCCA. The net effects of insertion of the two nucleotides are frameshifts at amino acid positions 104 and 106. In strain 17syn+ there are additional insertions and deletions which occur outside the coding domain of the genes for ICP34.5 of other strains; these occur at positions corresponding to nucleotides 1044 to 1064 of strain F. With the exception of the missing 21 base pairs predicted to encode seven amino acids in MGH-10 and the additional arginine residue in MGH-10 and CVG-2, the differences among strains MGH-10, CVG-2, and F are minor. MGH-10 has a total of five nucleotide substitutions resulting in three amino acid differences. CVG-2 has 11 nucleotide substitutions resulting in five amino acid differences from F. The ICP34.5-coding domain in strain F contains 10 repeats of the sequence CCCCCGCGA, which encodes the trimer Ala-Thr-Pro. The numbers of repeats in the coding domains of the other strains are five for 17syn+ and six for strains MGH-10 and CVG-2. Because of the frameshift, the repeat sequence in strain 17syn+ translates as Pro-Arg-Pro. The open reading frame in HSV-1(F) is predicted to encode 263 amino acids, i.e., less than the otherwise-reported 358 amino acids [Chou et al., *J. Virol.*, 57, 629-637 (1986)].

2072627

- 17 -

A proposal that a gene exists which encodes ICP34.5 is related to the finding that the terminal  $\alpha$  sequence in juxtaposition to a reporter gene is able to promote expression [Chou et al., J. Virol., 57, 629-637 (1986)]. However, the DNA that encodes ICP34.5 is difficult to sequence because it is G + C rich and contains long stretches of guanines and cytosines. Moreover, the 5'-untranscribed domain of the gene does not contain a TATAA box and is contained entirely within the terminal  $\alpha$  sequence that also contains numerous repetitive G + C-rich elements, unlike most HSV-1 genes [Chou et al., J. Virol., 57, 629-637 (1986)].

If the open reading frame were expressed, the close proximity and overlap with the terminal  $\alpha$  sequence may indicate that the gene product is involved in one of the several functions of the terminal  $\alpha$  sequence [Chou et al., Cell, 41, 803-811 (1985); Deiss et al., J. Virol., 59 605-618 (1986); Mocarski et al., Cell, 31, 7047-7051 (1981); Mocarski et al., Cell, 31, 89-97 (1982); and Varmuza et al., Cell, 41, 793-802 (1985)]. Several laboratories [Centifanto-Fitzgerald et al., J. Exp. Med., 155, 475-489 (1982); Javier et al., J. Virol., 72 1978-1984 (1987) and Meignier et al., J. Infect. Diseases, 158, 602-615 (1988)] report the mapping of a locus at or near the inverted repeat region which attenuates the ability of HSV-1 to cause central nervous system disease in mice.

The gene that specifies ICP34.5 contains 263 codons conserved in all three limited-passage strains, but not in the reported sequence of the HSV-1(17)syn+ strain. Nonconservation of the open reading frame that specifies ICP34.5 in the reported sequence of HSV-1(17)syn+ [McGeoch et al., J. Gen. Virol., 69, 1531-1574 (1986) and Perry et al., J. Gen. Virol., 69, 2831-2846 (1988)] indicates that the sequenced virus may have

2072627

- 18 -

accumulated mutations since its original isolation. Consistent with this view is the report in Taha et al., J. Gen. Virol., 70, 3073-3078 (1989) reporting that a variant of HSV-2 strain HG52 lacks 1.5 kbp covering the domain of the gene that specifies ICP34.5. the virus grows but is avirulent (50% lethal dose,  $>10^7$  PFU) in mice inoculated intracerebrally.

Although sequencing of the HSV-1 genome [McGeoch et al., J. Gen. Virol., 69, 1531-1574 (1988); McGeoch et al., Nucleic Acids Res., 14, 1727-1745 (1986) and Perry et al., J. Gen. Virol., 69, 2831-2846 (1988)] is useful, the knowledge that the nucleotide sequence of the ICP34.5 gene in three HSV-1 strains, i.e., HSV-1(F), HSV-1(CVG2), and HSV-1(MGH10), differs significantly from the reported sequence of the corresponding HSV-1(17)syn+ gene raises the possibility that additional mutations have accumulated in other genes of HSV-1(17)syn+ and underscores the need to sequence regions of particular interest in more than one virus strain to ensure that the sequence approximates that of a wildtype virus and does not reflect accumulated mutations of serial passages outside a human host.

The role of the gene for ICP34.5 in determining the ability of a virus to multiply and destroy central nervous system tissue is of particular interest. Of the viruses examined, two have been extensively tested for virulence in mice. HSV-1(F), isolated from a recurrent facial lesion, is of moderate virulence, with a 50% lethal dose of approximately 100 PFU by intracerebral inoculation of mice. In contrast, MGH-10, derived from a case of human encephalitis, has a 50% lethal dose of 1 to 5 PFU by the same route in identical mouse strains [Meignier et al., J. Infect. Diseases, 158, 602-614 (1988)].

2072627

- 19 -

EXAMPLE 2CONSTRUCTION OF RECOMBINANT PLASMID pRB3976

5 The evidence that the open reading frame  
between the terminal a sequence and the open reading  
frame that encodes  $\alpha 0$  specifies a protein and that this  
protein is made in lytically infected cells is based in  
part on the reactivity of infected-cell extracts with a  
polyclonal antibody to a synthetic oligopeptide having 10  
repeats of (Ala-Thr-Pro) with a Cys following the tenth  
10 repeat.

Inasmuch as the divergence in the nucleotide  
sequence of strain HSV-(17)syn+ occurs before the  
predicted repeat Ala-Thr-Pro in HSV-1(F), it could be  
argued that the antibody to the trimer repeat reacts with  
15 a different protein containing such repeats. It could  
also be argued that truncation of the open reading frame  
in recombinant virus R3615 is coincidental with the  
selection of a variant virus containing fewer Ala-Thr-Pro  
repeats.

20 To demonstrate unambiguously that a rabbit  
polyclonal antibody to the repeat Ala-Thr-Pro reacts with  
the protein predicted to be encoded by the nucleotide  
sequence of HSV-1(F), an oligonucleotide that encodes the  
amino acids 121 to 135 containing an epitope of ICP4 in  
25 frame with the open reading frame at the NcoI site was  
inserted as illustrated in FIG. 3. Hubenthal-Voss et al.,  
J. Virol., 62, 454-462 (1988) reports that the synthetic  
polypeptide that encodes this sequence reacts with  
monoclonal antibody H943 to ICP4. The recombinant virus  
30 containing this epitope was designated R3976.

An oligonucleotide 50 bases long and its  
complement sequence designed to end in NcoI restriction  
enzyme cleavage sites were synthesized as described in  
Example 1 and as illustrated in FIG. 3.

35 The two oligonucleotides were then mixed at an

2072627

- 20 -

equal molar ratio, heated to 80°C., and allowed to anneal by being cooled slowly to room temperature. The annealed DNA was then ligated to a cloned DNA fragment containing the gene for ICP34.5 and cleaved with NcoI. In the gene  
5 for ICP34.5, the NcoI site is located at the methionine initiation codon. The resulting plasmid, pRB3976, was sequenced (data not shown) to confirm the appropriate insertion as shown and then used in transfection experiments with the parental viral DNA. R3615, to  
10 generate recombinant virus R3976.

In FIG. 3, within the sequence arrangement of HSV-1(F), the a sequence identifies the terminal 500-base-pair sequence present in the direct orientation at the two genomic termini and in the inverted orientation  
15 at the junction between the L and S components of the genome [Sheldrick et al., Cold Spring Harbor Symp. Quant. Biol., 39, 667-678 (1975) and Wadsworth et al., J. Virol., 15, 1487-1497 (1975)]. b and c are large inverted repeats, 9 and 6 kbp in length, respectively,  
20 which, flank the L and S components of the virus. In FIG. 3, the extent of the deletion of sequences at the L-S component junction of recombinant virus R3410 is shown by the interrupted line [Ackermann et al., J. Virol., 58, 843-850 (1986)].

In FIG. 3, within the sequence arrangement of R3615 showing insertion of an  $\alpha 27$ -tk chimeric gene into the BstEII site of the gene for ICP34.5, the insert contains at its terminus distal from the a sequence the regulatory domain, the 5'-transcribed noncoding domain,  
30 and the methionine initiation codon of glycoprotein H. The initiation codon was fused in frame with amino acid 27 of ICP34.5, generating a truncated form of this protein [Ackermann et al., J. Virol., 58, 843-850 (1986)].

2072627

- 21 -

EXAMPLE 3ELECTROPHORESIS OF CELL EXTRACTS

To ensure that the antibody to a predicted repeat sequence, Ala-Thr-Pro, reacted with ICP34.5 rather than with a heterologous protein with a similar repeat sequence, a short sequence of 45 nucleotides that encodes an epitope characteristic of another HSV-1 gene [Hubenthal-Voss et al., J. Virol., 62, 454-462 (1988)] was inserted near the 5' terminus of the ICP34.5-coding domain.

In the sequence arrangement and construction of recombinant virus R3976 carrying the epitope encoded by ICP4 amino acids 121 to 135 [Hubenthal-Voss et al., J. Virol., 62, 454-462 (1988)], the sequence that encodes these amino acids was inserted at the NcoI site of ICP34.5. At the bottom of FIG. 3 is the nucleotide sequence (coding strand, SEQ ID NO:5; complementary strand, SEQ ID NO:6) and predicted amino acid sequence (SEQ ID NO:4) of the insert on plasmid pRB3976 that was inserted into recombinant virus R3976 in frame with the gene for ICP34.5 that and which encodes the ICP4 epitope specifically recognized by monoclonal antibody H943.

Monolayer cultures containing  $4 \times 10^6$  Vero cells were exposed to 5 to 10 PFU of recombinant viruses per cell for 2 hours. After adsorption, the inoculum was replaced with mixture 199 supplemented with 1% calf serum and maintained for 12 hours. The cells were then labeled with 10  $\mu$ Ci of [ $^{35}$ S]methionine (Dupont, NEN Research Products) in the same medium but without methionine for an additional 12 hours. The cells were then harvested, washed once with phosphate-buffered saline, pelleted by centrifugation at 4,000 rpm for 5 min and suspended in disruption buffer which consisted of 0.05 M Tris (pH 7.0), 8.5% (wt/vol) sucrose, 5% (vol/vol) 2  $\beta$ -mercaptoethanol, and 2% (vol/vol) sodium dodecyl sulfate.

- 22 -

5 Extracts were then boiled for 2 min in water, disrupted by sonication in a Branson Sonifier<sup>TM</sup> 200 (SmithKline, King of Prussia, Pennsylvania) three times for 3 sec each time, and then subjected to electrophoresis in denaturing polyacrylamide gels.

10 The polypeptides were separated electrophoretically on denaturing 10% polyacrylamide gels, transferred electrically to nitrocellulose sheets, and reacted with rabbit antiserum R4 or monoclonal antibody H943 by using Vectastain<sup>TM</sup> ABC kits specifically for rabbit and mouse antibodies (Vector Laboratories Inc., Burlingame, California) as previously described [Ackermann et al., J. Virol., 58, 843-850 (1986) and Braun et al., J. Virol., 46, 103-112 (1983)].

15 The results are illustrated in FIG. 4 wherein autoradiographic images (A and C) and photographs of lysates of cells mock infected or infected with HSV-1(F) or recombinants that were separated electrophoretically in denaturing gels, transferred electrically to a  
20 nitrocellulose sheet, and stained with monoclonal antibody H943 (B) or rabbit polyclonal antibody R4 (D) are presented. The numbers to the right of panels A and C indicate the infected-cell protein designations of Honess et al., J. Virol., 12, 1347-1365 (1973) and Morse  
25 et al., J. Virol., 26, 398-410 (1978).

Lysates of R3976-infected cells exhibited a band which reacted with both monoclonal antibody H943 and polyclonal rabbit serum R4 (FIG. 4). This band migrated more slowly than the band formed by lysates of HSV-1(F)-  
30 infected cells which reacted with R4 rabbit serum only. The band containing the truncated ICP34.5 protein reacted only with rabbit R4 serum and migrated faster than the authentic protein specified by HSV-1(F). These results provide definitive evidence supporting the existence of  
35 the open reading frame by showing that insertion of a

- 23 -

2072627

foreign epitope into the gene in frame resulted in expression of both the predicted trimer Ala-Thr-Pro and the foreign epitope in the same protein. The repeated trimer must be in ICP34.5 and not in some other protein.

5

EXAMPLE 4IMMUNIZATION ROUTES, DOSAGES AND INDICATIONS

A human host is preferably inoculated with a vaccine comprising an immunity-inducing dose of one or more of the live vaccinal recombinant strains of the invention by the parenteral route, preferably by intramuscular or subcutaneous injection. Also, inoculation may be effected by surface scarification, or by inoculation of a body cavity. Typically, one or several inoculations of between about 10 and 1,000,000 pfu each, as measured in susceptible human or nonhuman primate cell lines, are sufficient to effect immunization of a human host.

Indications for vaccination include:

- a) a desire or need to boost the level of immunity of the host;
- b) a lack of immunity in the face of a high probability of natural infection; or
- c) a lack of immunity and a likelihood that the subject will become immunologically compromised due to immunosuppressive therapy in the immediate or near future.

The vaccine according to the present invention may be conveniently utilized in liquid form or in freeze-dried form, in the latter case in combination with one or more suitable preservative and protective agents to protect the vaccinal strains during the freeze drying process.

To test the possible role of the infected cell protein 34.5 (ICP34.5), the product of the  $\gamma_{134.5}$  gene, a

- 24 -

2072627

series of four viruses were constructed. These viruses, schematically represented in FIG. 5, were constructed using the procedures described by Post et al., Cell, 227 (1981) as follows.

5

EXAMPLE 5CONSTRUCTION AND TESTING OF VIRUS R4002

10 Rabbit skin cells of a convenient cell line (VERO cells available from the American Type Culture Collection may also be used) were cotransfected with intact DNA of HSV-1(F) $\Delta$ 305 deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland under accession number ATCC VR2279 a virus from which a portion of the tk gene was specifically deleted [Post et al., Cell, 227 (1981)], and with a fragment of 15 plasmid pRB3615, which contains the  $\alpha$ 27-tk gene inserted into the BstEII site within the  $\gamma$ <sub>134.5</sub> gene contained in the BamHI S fragment. Recombinant virus of the tk<sup>+</sup> type were then selected and plaque-purified on human 143TK-cells in medium containing HAT hypoxanthine, aminopterin, and thymidine ("HAT Medium"). 20

The fragment, including the  $\alpha$ 27-tk gene, contains a 5' non-transcribed promoter, a transcribed non-coding sequence, and an initiating methionine codon of the glycoprotein H gene downstream from the tk gene 25 [Chou et al., J. Virol., 57 629 (1986)]. The BstEII site into which the  $\alpha$ 27-tk fragment was inserted is immediately upstream of the codon 29 of the  $\gamma$ <sub>134.5</sub> open reading frame. As a consequence of the insertion, the initiating codon of glycoprotein H was fused in frame and became the initiating codon of the truncated open reading 30 frame of the  $\gamma$ <sub>134.5</sub> gene as shown in the row of FIG. 5 identified as " $\gamma$ <sub>134.5F</sub>."

FIG. 5 is a schematic representation of the sequence arrangements of the genome of wild type strain

2072627

- 25 -

HSV-1 strain F [HSV-1(F)] and of recombinant viruses derived from it. In FIG. 5, N, Be, S, St are abbreviations for NcoI, BstEIII, SacI and StuI restriction endonucleases (available from New England, Biolabs, Beverly, Massachusetts), respectively. The numbers in parentheses are the tk<sup>+</sup> version of each construct tested in mice.

To the right of "HSV-1(F)Δ305" in FIG. 5, is shown the sequence arrangement of a deletion mutant of HSV-1(F) deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland under accession number ATCC VR2279 on August 14, 1990. HSV-1 DNA consists of two components, long and short, each consisting of unique sequences flanked by inverted repeats. The open rectangles identify the inverted repeats ab, b'a'c, and ca [Wadsworth et al., J. Virol., 15, 1487 (1975)]. The HSV-(F) a sequence consists of approximately 500 bp and is present in direct orientation at the two genomic termini and in the inverted orientation at the junction between the long and short two components, Wadsworth et al., supra. The b and c sequences are approximately 9 and 6 Kbp long, respectively, Wadsworth et al., supra. The triangle marked "TK" identifies the position of the tk gene and of the BglIII-Sac sequence of BamHI Q fragment deleted from HSV-1(F)Δ305.

In FIG. 5, the lines to the left of "γ<sub>1</sub>34.5 genome" and to the left of "WT," show that the b sequences contain the gene specifying ICP34.5 and ICPO and, since the b sequence is repeated in an inverted orientation, there are two copies of these genes per genome. The construction of the α27-tk fragment containing portions of the glycoprotein H gene (shown to the left of "Truncated γ<sub>1</sub>34.5" is described in Chou et al., J. Virol., 57, 629 (1986); Ackermann et al., J.

2072627

- 26 -

Virology, 58, 843 (1986); and Chou et al., J. Virology, 64, 1014 (1990)]. The construction of pRB3615 is described in Chou et al., J. Virology, 57, 629 (1986).

Of 20 tk<sup>+</sup> recombinant viruses screened, two were found to specify only the predicted truncated product of the chimeric  $\gamma_{134.5}$  gene and one, designated as R4002, was analyzed for the presence of the  $\alpha 27$ -tk gene insert in both copies of the  $\gamma_{134.5}$  gene. Plasmids and viral DNAs were digested with BamHI or, in case of the R4009, with both BamHI and SpeI. A fragment NcoI to SphI contained entirely within the coding sequences of  $\gamma_{134.5}$  (left panel) and the BamHI Q fragment of HSV-1(F) (right panel) were used as hybridization probes. The probes were labeled by nick translation of the entire plasmid DNAs with [ $\alpha$ -<sup>32</sup>]dCTP and reagents provided in a kit by New England Nuclear (Boston, Massachusetts). DNAs limit-digested with BamHI or both BamHI and SpeI were electrophoretically separated on 0.8% agarose gels in 90 mM Tris-Phosphate buffer at 40 V overnight. The DNA was then transferred by gravity to two nitrocellulose sheets sandwiching the gel and hybridized overnight with the respective probes.

FIG. 6 is a photographic reproduction of an autoradiographic image of electrophoretically separated digests of plasmid, wild type and mutant virus DNA, transferred to a solid substrate and hybridized with the labeled probes for the presence of  $\gamma_{134.5}$  and tk genes. Results for DNA digested with BamHI are shown in the left panel (except for lane 10), while results for DNA digested with BamHI and SpeI are shown in the left panel, lane 10, and in the right panel of FIG. 6.

$\gamma_{134.5}$  maps in BamHI S and SP fragments which form a characteristic ladder of bands at 500 base pair increments. The ladders are a consequence of the variable number of a sequences in the repeats flanking

the unique sequences of the L component. Inasmuch as BamHI cleaves the viral genome within the inverted repeats but not at the junction between the L and S components, BamHI S is the terminal fragment of the viral genome at the terminus of the long component, whereas BamHI SP is a fragment formed by the fusion of the terminal BamHI P, the terminal BamHI fragment of the short component. Bands of BamHI S and its deleted version ( $\Delta$ BamHI S), BamHI SP and  $\Delta$ BamHI SP, and BamHI Q and  $\Delta$ BamHI Q are indicated.

In FIG. 6, band 1 represents the 1.7 Kbp  $\alpha$ 27-tk insert into the BamHI SP fragment in R4002 and therefore this fragment reacted with both labeled probes (lanes numbered 4 in both panels). Band 2 represents the same insertion into the BamHI S fragment.

As indicated in the fourth lanes of FIG. 6, left and right panels, the  $\alpha$ 27-tk gene is inserted in both copies (designated 1 and 2 next to bands in the fourth lanes) of the  $\gamma$ <sub>34.5</sub> gene.

Lysates of cells were infected with HSV-1(F) or "mock infected" by exposure to Medium 199V for the same amount and recombinant viruses were separated electrophoretically in denaturing polyacrylamide (10%) gels, transferred electrically to a nitrocellulose sheet, and stained with rabbit polyclonal antibody R4 described elsewhere [Ackermann et al., J. Virol., 58, 843 (1986) and Chou et al., Cell, 41, 803 (1985)]. Replicate cultures of Vero cells were infected and labeled with [<sup>35</sup>S]methionine (New England Nuclear, Boston, Massachusetts) from 12 to 24 hours post infection. The procedures were as described [Ackermann et al., J. Virol., 58, 843 (1986) and Chou et al., J. Virol., 64, 1014 (1990)] except that the bound antibody was made apparent with the alkaline phosphatase substrate system supplied by Promega Inc. (Madison, Wisconsin).

2072627

- 28 -

The results are illustrated in FIG. 7, the left panel of which is a photographic reproduction of an autoradiographic image, and the right panel of which is a photograph of an alkaline phosphatase gel (as described above). Infected cell proteins were designated by number according to Honess et al., *J. Virol.*, 12, 1346 (1973). Also shown is that this virus specifies only the truncated form of ICP34.5 (See in FIG. 15 right panel, lane 3, a single, fast migrating band for ICP34.5). The amounts of the native ICP34.5 protein detected in these and previous studies were generally low [Ackermann et al., *J. Virol.*, 58, 843 (1986)]. The chimeric genes formed by the fusion of the 5' transcribed non-coding region and the initiating codon of glycoprotein H in frame with the truncated  $\gamma_{134.5}$  gene were expressed far more efficiently than the native genes.

As illustrated in FIG. 5, in the lines to the left of "WT" and "Truncated  $\gamma_{134.5}$ ," recombinant virus R4002 contains a thymidine kinase (*tk*) gene driven by the promoter of the  $\alpha 27$  gene ( $\alpha 27$ -*tk*) is inserted in both copies of the ICP34.5 coding sequences.

This is shown in FIG. 7, line 3, where only the band, the band corresponding to a truncated ICP34.5 appears, demonstrating that all ICP34.5 is made in those cells from a truncated gene. R4002 was used as a parent strain to generate other recombinant viruses used.

#### EXAMPLE 6

##### CONSTRUCTION AND TESTING OF VIRUSES R3616 AND R3617

A recombinant virus R3617 (as illustrated by the line in FIG. 5 to the right of "R3617"), lacking 1 Kbp of DNA in each copy of the  $\gamma_{134.5}$  gene, was generated by co-transfecting rabbit skin cells with intact R4002 DNA and the DNA of plasmid pRB3616. In plasmid pRB3616, the sequences containing most of the coding domain of

2072627

- 29 -

$\gamma_134.5'$  i.e., those located between BstEII and StuI sites within the BamHI S fragment of HSV-1 strain F, had been deleted (FIG. 5, line 5 from top). To generate pRB3616, plasmid pRB143 [Post et al., Proc. Nat'l. Acad. Sci. (USA), 77, 4201 (1980)] was digested with BstEII and StuI, blunt-ended with T4 polymerase, and religated.

The progeny of the transfection were plated on 143TK- cells overlaid with medium containing BUdR to select for tk viruses. Because the tk gene is present in both copies of the  $\gamma_134.5$  gene in R4002, the selected progeny of the transfection contain deletions in both copies. The selected tk virus, designated as R3617, was analyzed for the presence of the deletion in both copies of the  $\gamma_134.5$  gene (data not shown). The  $\gamma_134.5$  gene was not present. See, e.g., FIG. 6, for R3616 where the tk gene is present in one copy at the normal position after repair.

For assays of neurovirulence, the deletion in the native tk gene of R3617, which traces its origin from HSV-1(F) $\Delta$ 305, was repaired. This was done by cotransfection of rabbit skin cells with intact R3617 DNA and a BamHI Q fragment containing the tk gene. The virus selected for tk<sup>+</sup> phenotype in 143TK cells was designated as R3616. This virus contains a wild type BamHI Q fragment (as shown in FIG. 6, right panel, lane 6) and does not make ICP34.5 (as shown in FIG. 6, right panel).

R3616 was deposited under accession number ATCC VR2280 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 on August 14, 1990.

- 30 -

2072627

EXAMPLE 7CONSTRUCTION AND TESTING OF VIRUS HSV-1(F)R

To ascertain that the phenotype of R3616 indeed reflects the deletion in the  $\gamma_{134.5}$  gene, the  $\gamma_{134.5}$  sequences deleted from R3616 were restored by cotransfecting rabbit skin cells with intact R3617 DNA, the HSV-1(F) BamHI Q DNA fragment containing the intact tk gene and the BamHI SP DNA fragment containing the intact  $\gamma_{134.5}$  gene in the molar ratios of 1:1:10, respectively. Viruses of the tk<sup>+</sup> type were then selected in 143TK<sup>-</sup> cells overlaid with medium containing HAT. The tk<sup>+</sup> candidates were then screened for the presence of wild type tk and  $\gamma_{134.5}$  genes.

As expected, the selected virus designated as HSV-1(F)R schematically illustrated to the right of "HSV-1(F)R" in FIG. 13 contained a wild type (tk<sup>+</sup>) BamHI Q fragment (as shown by comparison of FIG. 6), right panel lanes 2 and 7), a wild type terminal L component fragment (as shown by comparison of FIG. 6), left panel lanes 2, 7, and 8), and expressed ICP34.5 as shown in FIG. 7, right panel, lane 6).

EXAMPLE 8CONSTRUCTION OF VIRUS R4010

To eliminate the possibility that the phenotype of R3616 reflects deletion in cryptic open reading frames, a virus was constructed to contain translational stop codons in all three reading frames in the beginning of ICP34.5 coding sequence. This virus was designated R4010, and is illustrated in FIG. 5 to the right of "R4010." A 20 base oligonucleotide containing translational stop codons and their complement sequences was constructed in an Applied Biosystems (Foster City, California) 380D DNA synthesizer, mixed at equal molar ratio, heated to 80°C., and allowed to cool slowly to room

- 31 -

2072627

temperature.

GTAACCTAGACTAGTCTAGC\*\*\*\*\*

\*\*\*\*GATCTGATCAGATCGCATTG

5 The asterisks (\*\*\*\*) in this sequence, and in all  
sequences in FIG. 5 designate nucleotides from a vector  
plasmid that form cohesive ends with the synthesized  
oligomers. The upper strand (also shown in FIG. 5) is  
SEQ ID NO:7, and the lower strand (also shown in FIG. 5)  
10 is SEQ ID NO:8. The annealed DNA was inserted into one  
HSV-1(F) BamHI S fragment at the BstEII site of the  
plasmid pR5143. The resulting plasmid pRB4009 contained  
a stop codon inserted in the beginning of the ICP34.5  
coding sequence. The 20mer DNA insertion also contained  
15 a SpeI restriction site which allowed rapid verification  
of the presence of the insert.

To generate the recombinant virus R4010, rabbit  
skin cells were cotransfected with the intact DNA of  
R4002 and the pRB4009 plasmid DNA. Recombinants of the  
tk<sup>-</sup> type were selected in 143TK<sup>-</sup> cells in medium containing  
20 BudR. The tk<sup>+</sup> version of this virus, designated as  
R4009, was generated by cotransfection of intact tk<sup>-</sup> R4010  
DNA with HSV-1(F) BamHI Q DNA fragment, and selection of  
tk<sup>+</sup> progeny. The virus selected for neurovirulence  
studies, R4009, contained the SpeI site in both BamHI S  
25 and SP fragments as shown by a comparison of FIG. 14,  
left panel, lanes 9 and 10) and did not express ICP34.5  
as shown by FIG. 7, right panel lane 7).

R4009 was deposited under accession number ATCC  
VR2278 with the American Type Culture Collection, 12301  
30 Parklawn Drive, Rockville, Maryland 20852 on August 14,  
1990.

#### EXAMPLE 9

#### CONSTRUCTION AND TESTING OF VIRUS R4004

R4004, FIG. 5 last line, is a recombinant virus

2072627

- 32 -

produced by insertion of a sequence (SEQ ID NO:5 and SEQ ID NO:6) encoding 16 amino acids (SEQ ID NO:4), as illustrated in FIG. 7 to the right of "R4004." This sequence is the epitope of the monoclonal antibody H943 reactive with a viral protein designated as ICP4 [Hubenthal-Voss et al., *J. Virol.*, 62, 454 (1988)]. R4004 was generated by cotransfecting intact R4002 DNA and the DNA of plasmid pRB3976 containing the insert, and *tk* progeny were analyzed for the presence of the insert. The construction of recombinant plasmid pR53976 is described elsewhere [Chou et al., *J. Virol.*, 57, 629 (1986) and Chou et al., *J. Virol.*, 64, 1014 (1990)] except that the sequence was inserted into both copies of the  $\gamma$ <sub>134.5</sub> gene rather than into a recombinant virus which had only one copy of the gene. This insertion merely truncates but does not inactivate the ICP34.5 protein.

That DNA encoding the epitope is inserted in both copies of the gene is shown in FIG. 7 by the coincident reactivity of the rabbit antibody to ICP34.5 at the band corresponding to ICP4. If the gene encoding the epitope were present in only one copy, two bands would be present.

For neurovirulence studies, the *tk* gene was restored to R4004 to form recombinant virus R4003 as described above. The DNA sequence was inserted in frame at the NcoI site at the initiating methionine codon of the  $\gamma$ <sub>134.5</sub> gene. The insert regenerated the initiating methionine codon and generated a methionine codon between the epitope and the remainder of ICP34.5.

The chimeric ICP34.5 specified by R4003 migrated more slowly in denaturing polyacrylamide gels (as seen in FIG. 7, right panel, lane 4) than the protein produced by other viruses illustrated in FIG. 7 because of the increased molecular weight due to the insertion of the epitope. The reactivity of the inserted epitope with

- 33 -

2072627

monoclonal antibody H943 is reported elsewhere [Chou et al., Cell, 41, 803 (1985)] and is not shown here.

#### EXAMPLE 10

##### CULTURE AND NEUROVIRULENCE STUDIES

5           Plaque morphology and size of all of the recombinants were similar to those of the wild type parent, HSV-1(F) when plated on VERO, 143TK and rabbit skin cell lines. Whereas HSV-1(F)R and R4003 replicated as well as the wild type virus in replicate cultures of  
10   Vero cells, the yields of R3616 and R4009 were reduced 3 to 4 fold.

          Neurovirulence studies were done on female BalB/C mice obtained at 21 days of age (weight  $9.4 \pm 1.8$  gm) from Charles River Breeding Laboratories in Raleigh,  
15   North Carolina. The tk gene was restored in all recombinant viruses tested in mice. Viruses HSV-1(F), R3617, HSV-1(F)R, R4009 and R4003 were diluted in minimal essential medium containing Earle's salts and 10% fetal bovine serum, penicillin and gentamicin. The mice were  
20   inoculated intracerebrally into the right cerebral hemisphere with dilutions of virus using a 26-gauge needle. The volume delivered was 0.03 ml, and each dilution of virus was tested in groups of 10 mice. The animals were checked daily for mortality for 21 days.  
25   The LD<sub>50</sub> was calculated with the aid of the "Dose Effect Analysis" computer program for Elevier Biosoft, Cambridge, United Kingdom. The results indicate the comparative ability of wild type and recombinant viruses to cause death after intracerebral inoculation of mice as  
30   provided in Table 1.

2072627

- 34 -

TABLE 1

|    | Virus in<br>the Inoculum | Genotype                                                                                  | pfu/LD50                 |
|----|--------------------------|-------------------------------------------------------------------------------------------|--------------------------|
| 5  | HSV-1(F)<br>R3616        | Wild type parent virus<br>1000 bp deletion in the<br>$\gamma_134.5$                       | 420<br><br>>1,200,000    |
|    | HSV-1(F),<br>R4009       | restoration of $\gamma_134.5$<br>and tk                                                   | 130                      |
| 10 | R4003                    | Stop codon in $\gamma_134.5$<br>Monoclonal antibody epitope<br>inserted at the N terminal | >10,000,000<br><br>4,200 |

15 Although ICP34.5 was not essential for growth of HSV-1 in cells in culture, the results of the studies shown in Table 1 indicate that the deletion or  
20 termination of translation of the  $\gamma_134.5$  had a very profound effect on the virulence of the virus. Thus, all of the mice inoculated with the highest concentration of R3616 survived. In the case of R4009, only 3 of 10 mice died as a result of inoculation with the highest  
25 concentration of virus. Virus HSV-1(F)R, in which the  $\gamma_134.5$  gene was restored, exhibited the virulence of the parent virus.

25 The wild type virus and all of the recombinants have identical surface glycoproteins necessary for attachment and penetration into brain cells. Injection of  $10^6$  pfu into the brain should result in infection and death of a significant number of the brain cells. Death following intracerebral inoculation results from viral replication, spread from cell to cell, and cell  
30 destruction before the immune system has a chance to act. Titrations of brain tissue suspended in minimal essential medium containing Eagle's salts and 10% fetal calf serum showed that the brains of animals inoculated with the viruses which failed to make ICP34.5 contained very

- 35 -

2072627

little virus. Thus, for the R3616 and R4009 viruses, the recovery was 120 and 100 pfu per gram of brain tissue, respectively. In contrast, the amounts of virus recovered from mice inoculated with HSV-1(F)R and R4003 were  $6 \times 10^6$  and  $4 \times 10^6$ , respectively. These results indicate that the failure of the two recombinant viruses to cause death must be related to poor spread of virus in neuronal tissue, and this may be a reflection of the inability of mutant viruses to replicate in the central nervous system (CNS).

As a general principle, all deletion mutants in coding sequences generated and tested to date [Meignier et al., J. Infect. Dis., 158 602 (1988) and Meignier et al., Virology, 162, 251 (1987)] have a reduced capacity to cause disease in experimental animals. None of the HSV-1 mutants unambiguously carrying a deletion in a single gene, however, exhibits as drastic a decrease in ability to cause death in experimental animals as those according to the present invention.

The loss of capacity to replicate in the CNS and cause death is not due to rearrangement of DNA as a consequence of the deletion. Identical loss of capacity to replicate in the CNS was obtained by insertion of the stop codons. Furthermore, the loss of virulence by the mutants containing the stop codons was not a consequence of some rearrangement of the DNA sequences at the terminus of the genome since insertion of the ICP4 epitope, a much larger insert, into the coding sequence had a marginal effect on the ability of the virus to replicate in the CNS. These data also indicate that the modification of the N terminus of the protein did not grossly debilitate the capacity of the protein to function in the mouse brain. While the function of ICP34.5 is not known, it is not essential for growth in cells in culture. The slight decrease in replication of

5 this virus in cells in culture is not concordant with the  
loss of its ability to multiply and destroy the CNS in  
mice. The failure to recover virus from the CNS suggests  
that brain cells do not express genes whose products can  
substitute for  $\gamma_134.5$  gene product and complement the  
deletion mutants. ICP34.5 extends the host range of HSV-  
1 and enables the virus to replicate in the CNS. From  
this point of view, the protein is necessary for the  
dissemination of the virus from cell to cell and  
10 destruction of brain tissue characteristic of human  
encephalitis.

Gross deletions in a viral genome are reported  
to result in decreased capacity to cause death in  
experimental animals [Centifanto-Fitzgerald et al., J.  
15 Exp. Med., 155, 475 (1982) and Meignier et al., J.  
Infect. Dis., 158, 602 (1988)]. In the above examples,  
rearrangements in the viral genome, insertion of  
nonhomologous DNA, and deletion of cryptic open reading  
frames as the cause of the loss of neurovirulence have  
20 been excluded as the bases for this decreased capacity.  
The above examples directly relate the capacity to  
replicate in CNS, the hallmarks of neurovirulence, to the  
synthesis and expression of a specific protein made in  
relatively non-abundant amounts and not essential for  
25 replication in cultured cells. By its properties, the  
product of the  $\gamma_134.5$  gene comes closest of all known  
viral proteins to the definition of an HSV neurovirulence  
factor.

- 37 -

2072627

EXAMPLE 11

## LATENCY STUDIES

Five Balb/c mice in each of 4 groups were anesthetized, a cornea was scarified using a hypodermic needle, and the cornea was bathed in a viral suspension of  $1 \times 10^7$  pfu or  $1 \times 10^8$  pfu of virus as indicated in Table 2. At 28 days post infection the trigeminal ganglia were removed from anesthetized and exsanguinated mice. The ganglia were pooled from each mouse, cut into small pieces and incubated for 3-4 days before plating on VERO cells. Plaques were counted 3 days later, with results as shown in Table 2.

2072627

TABLE 2

| <u>1 X 10<sup>7</sup> PFU</u> |                | <u>1 X 10<sup>8</sup> PFU</u>     |                                   |
|-------------------------------|----------------|-----------------------------------|-----------------------------------|
| <u>Virus Strains</u>          | <u>Mouse #</u> | <u>PFU recovered from ganglia</u> | <u>PFU recovered from ganglia</u> |
| Parental                      | 1              | 3 X 10 <sup>3</sup>               | 1 dead--day 13                    |
|                               | 2              | 3 X 10 <sup>1</sup>               | 2 2.5 X 10 <sup>2</sup>           |
|                               | 3              | 4 X 10 <sup>3</sup>               | 3 1.9 X 10 <sup>3</sup>           |
|                               | 4              | 5 X 10 <sup>1</sup>               | 4 1 X 10 <sup>2</sup>             |
|                               | 5              | 2 X 10 <sup>2</sup>               | 5 0                               |
| Deletion                      | 1              | 0                                 |                                   |
|                               | 2              | 0                                 |                                   |
|                               | 3              | 0                                 |                                   |
|                               | 4              | 0                                 |                                   |
|                               | 5              | 0                                 |                                   |

2072627

TABLE 2 (Cont.d)

| <u>1 x 10<sup>7</sup> PFU</u> |                | <u>1 x 10<sup>8</sup> PFU</u> |                      |
|-------------------------------|----------------|-------------------------------|----------------------|
| <u>Virus Strains</u>          | <u>Mouse #</u> | <u>PFU recovered</u>          | <u>PFU recovered</u> |
|                               |                | <u>from ganglia</u>           | <u>from ganglia</u>  |
| Stop Codon                    | 1              | 0                             | 1                    |
|                               | 2              | 0                             | 2                    |
|                               | 3              | 0                             | 3                    |
|                               | 4              | 0                             | 4                    |
|                               | 5              | 0                             | 5                    |

2072627

| <u>1 X 10<sup>7</sup> PFU</u> |                | <u>5 X 10<sup>7</sup> PFU</u> |                       |
|-------------------------------|----------------|-------------------------------|-----------------------|
| <u>Virus Strains</u>          | <u>Mouse #</u> | <u>PFU recovered</u>          | <u>Mouse #</u>        |
|                               |                | <u>from ganglia</u>           | <u>PFU recovered</u>  |
|                               |                |                               | <u>from ganglia</u>   |
| Restored                      | 1              | 4 X 10 <sup>1</sup>           | 1                     |
|                               | 2              | 1 X 10                        | 2                     |
|                               | 3              | 0                             | 3                     |
|                               | 4              | 0                             | 4                     |
|                               | 5              | 0                             | 5                     |
|                               |                |                               | 1.4 X 10 <sup>3</sup> |
|                               |                |                               | 1.2 X 10 <sup>3</sup> |
|                               |                |                               | 1 X 10 <sup>2</sup>   |
|                               |                |                               | 5 X 10 <sup>1</sup>   |
|                               |                |                               | 1.8 X 10 <sup>3</sup> |

The results presented in Table 2 show that HSV viruses having a deletion in or stop codon inserted in the ICP34.5 gene poorly establish latency or do not reactivate.

5           Although the present invention has been described in terms of an HSV-1 construction, the ICP34.5 gene of HSV-2 may be modified according to the present invention. Although no gene is reported to be identified in the region of the deletion, Taha et al., J. Gen. Virol., 70, 3073-3078 (1989), reports a variant of HSV-2 strain HG52 having a deletion of 1.5 kbp including the domain of the gene that specified ICP34.5. The virus grows but is completely avirulent (50% lethal dose,  $>10^7$  PFU) in mice inoculated intracerebrally. Therefore, an HSV-2 virus which lacks an ICP34.5 gene encoding an active gene product may be produced according to the present invention just as in an HSV-1 virus according to the present invention, by insertion of a stop codon, or by a small deletion or insertion in the coding region of the ICP34.5 gene as determined by its homology to the HSV-1 ICP34.5 gene.

15           In addition to utility in immunizing a human host against wild type HSV-1 and HSV-2, the virus strains of the invention are believed to have utility in treating a subject infected with wild type HSV. Treatment can be effected using similar dosages and routes of administration as used in immunization, described above.

25           The foregoing detailed description is given for clearness of understanding only, and no unnecessary limitations are to be understood or inferred therefrom, as modifications within the scope of the invention will be obvious to those skilled in the art.

2072627

- 42 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: Roizman, Bernard

(ii) TITLE OF INVENTION: Recombinant Herpes Simplex Viruses  
Vaccines and Methods

(iii) NUMBER OF SEQUENCES: 8

## (iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &  
Bicknell

(B) STREET: Two First National Plaza Suite 2100

(C) CITY: Chicago

(D) STATE: Illinois

(E) COUNTRY: USA

(F) ZIP: 60603

## (v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

## (vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

## (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Gruber, Lewis S.

(B) REGISTRATION NUMBER: 30,060

(C) REFERENCE/DOCKET NUMBER: 27373/8235

## (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 312/346-5750

(B) TELEFAX: 312/984-9740

(C) TELEX: 25-3856

2072627

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1335 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

|                                                                    |     |
|--------------------------------------------------------------------|-----|
| TTTAAAGTCG CGGCGGCGCA GCCCGGGCCC CCCGCGGCCG AGACGAGCGA GTTAGACAGG  | 60  |
| CAAGCACTAC TCGCCTCTGC ACGCACATGC TTGCCTGTCA AACTCTACCA CCCCGGCAGC  | 120 |
| CTCTCTGTCT CCATGGCCCCG CCGCCGCCGC CATCGCGGCC CCCGCCGCC CCGGCCGCC   | 180 |
| GGGCCCACGG GCGCCGTCCC AACCGCACAG TCCCAGGTAA CCTCCACGCC CAACTCGGAA  | 240 |
| CCCGCGGTCA GGAGCGCGCC CGCGGCCGCC CCGCCGCCGC CCCCCGCCAG TGGGCCCCCG  | 300 |
| CCTTCTTGTT CGCTGCTGCT GCGCCAGTGG CTCCACGTTT CCGAGTCCGC GTCCGACGAC  | 360 |
| GACGATGACG ACGACTGGCC GGACAGCCCC CCGCCCGAGC CGGCGCCAGA GGCCCGGCCC  | 420 |
| ACCGCCGCCG CCCCCGCC CCGGTCCCCA CCGCCCGGCG CGGGCCCCGG GGGCGGGGCT    | 480 |
| AACCCCTCCC ACCCCCCCTC ACGCCCCTTC CGCCTTCCGC CGCGCCTCGC CCTCCGCCTG  | 540 |
| CGCGTCACCG CAGAGCACCT GGCGCGCCTG CGCCTGCGAC GCGCGGGCGG GGAGGGGGCG  | 600 |
| CCGGAGCCCC CCGCGACCCC CGCGACCCCC GCGACCCCCG CGACCCCCGC GACCCCCGCG  | 660 |
| ACCCCCGCGA CCCCCGCGAC CCCC GCGACC CCCGCGACCC CCGCGCGGGT GCGCTTCTCG | 720 |
| CCCCACGTCC GGGTGCGCCA CCTGGTGGTC TGGGCCTCGG CCGCCCGCCT GGCGCGCCGC  | 780 |
| GGCTCGTGGG CCCGCGAGCG GGCCGACCGG GCTCGGTTCC GGCGCCGGGT GGCGGAGGCC  | 840 |

2072627

- 44 -

GAGGCGGTCA TCGGGCCGTG CCTGGGGCCC GAGGCCCGTG CCCGGGCCCT GGCCCGCGGA 900  
GCCGGCCCCG CGAACTCGGT CTAACGTTAC ACCCGAGGCG GCCTGGGTCT TCCGCGGAGC 960  
TCCCGGGAGC TCCGCACCAA GCCGCTCTCC GGAGAGACGA TGGCAGGAGC CGCGCATATA 1020  
TACGCTGGGA GCCGGCCCCG CCCCAGGGCG GGCCCGCCCT CGGAGGGCGG GACTGGCCAA 1080  
TCGGCGGCCG CCAGCGCGGC GGGGCCCGGC CAACCAGCGT CCGCCGAGTC TTCGGGGCCC 1140  
GGCCCACTGG GCGGGAGTTA CCGCCCAGTG GGCCGGGCCG CCCACTTCCC GGTATGGTAA 1200  
TTAAAACTT ACAAGAGGCC TTGTTCCGCT TCCCGGTATG GTAATTAGAA ACTCATTAAT 1260  
GGGCGGCCCC GGCCGCCCTT CCCGCTTCCG GCAATTCCCG CGGCCCTTAA TGGGCAACCC 1320  
CGGTATTCCC CGCCT 1335

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 263 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Arg Arg Arg Arg His Arg Gly Pro Arg Arg Pro Arg Pro Pro  
1 5 10 15  
Gly Pro Thr Gly Ala Val Pro Thr Ala Gln Ser Gln Val Thr Ser Thr  
20 25 30  
Pro Asn Ser Glu Pro Ala Val Arg Ser Ala Pro Ala Ala Ala Pro Pro  
35 40 45  
Pro Pro Pro Ala Ser Gly Pro Pro Pro Ser Cys Ser Leu Leu Leu Arg

- 45 -

2072627

50 55 60

Gln Trp Leu His Val Pro Glu Ser Ala Ser Asp Asp Asp Asp Asp Asp  
65 70 75 80

Asp Trp Pro Asp Ser Pro Pro Pro Glu Pro Ala Pro Glu Ala Arg Pro  
85 90 95

Thr Ala Ala Ala Pro Arg Pro Arg Ser Pro Pro Pro Gly Ala Gly Pro  
100 105 110

Gly Gly Gly Ala Asn Pro Ser His Pro Pro Ser Arg Pro Phe Arg Leu  
115 120 125

Pro Pro Arg Leu Ala Leu Arg Leu Arg Val Thr Ala Glu His Leu Ala  
130 135 140

Arg Leu Arg Leu Arg Arg Ala Gly Gly Glu Gly Ala Pro Glu Pro Pro  
145 150 155 160

Ala Thr Pro Ala Thr Pro Ala Thr Pro Ala Thr Pro Ala Thr Pro Ala  
165 170 175

Thr Pro Ala Thr Pro Ala Thr Pro Ala Thr Pro Ala Thr Pro Ala Arg  
180 185 190

Val Arg Phe Ser Pro His Val Arg Val Arg His Leu Val Val Trp Ala  
195 200 205

Ser Ala Ala Arg Leu Ala Arg Arg Gly Ser Trp Ala Arg Glu Arg Ala  
210 215 220

Asp Arg Ala Arg Phe Arg Arg Arg Val Ala Glu Ala Glu Ala Val Ile  
225 230 235 240

Gly Pro Cys Leu Gly Pro Glu Ala Arg Ala Arg Ala Leu Ala Arg Gly  
245 250 255

Ala Gly Pro Ala Asn Ser Val  
260

- 46 -

2072627

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 355 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Ala Arg Arg Arg Arg His Arg Gly Pro Arg Arg Pro Arg Pro Pro  
1 5 10 15

Gly Pro Thr Gly Ala Val Pro Thr Ala Gln Ser Gln Val Thr Ser Thr  
20 25 30

Pro Asn Ser Glu Pro Ala Val Arg Ser Ala Pro Ala Ala Ala Pro Pro  
35 40 45

Pro Pro Pro Ala Gly Gly Pro Pro Pro Ser Cys Ser Leu Leu Leu Arg  
50 55 60

Gln Trp Leu His Val Pro Glu Ser Ala Ser Asp Asp Asp Asp Asp Asp  
65 70 75 80

Asp Trp Pro Asp Ser Pro Pro Pro Glu Ser Ala Pro Glu Ala Arg Pro  
85 90 95

Thr Ala Ala Ala Pro Arg Pro Pro Gly Pro His Arg Pro Ala Trp Ala  
100 105 110

Arg Gly Ala Gly Leu Thr Pro Pro Thr Pro Pro Arg Ala Pro Ser Ala  
115 120 125

Phe Arg Arg Ala Ser Pro Ser Ala Cys Ala Ser Pro Arg Ser Thr Trp  
130 135 140

Arg Ala Cys Ala Cys Asp Ala Arg Ala Gly Arg Gly Arg Arg Ser Pro  
145 150 155 160

2072627

Pro Arg Pro Pro Arg Pro Pro Arg Pro Pro Arg Pro Pro Arg Pro Pro  
165 170 175

Arg Gly Cys Ala Ser Arg Pro Thr Ser Gly Cys Ala Thr Trp Trp Ser  
180 185 190

Gly Pro Arg Pro Pro Ala Trp Arg Ala Ala Ala Arg Gly Pro Ala Ser  
195 200 205

Gly Pro Thr Gly Leu Gly Ser Gly Ala Gly Trp Arg Arg Pro Arg Arg  
210 215 220

Ser Ser Gly Arg Ala Trp Gly Pro Arg Pro Val Pro Gly Pro Trp Pro  
225 230 235 240

Ala Glu Pro Ala Arg Arg Thr Arg Ser Asn Val Thr Pro Glu Ala Ala  
245 250 255

Trp Val Phe Arg Gly Ala Pro Gly Ser Ser Ala Pro Ser Arg Ser Pro  
260 265 270

Glu Arg Arg Trp Gln Glu Pro Arg Ile Tyr Thr Leu Gly Ala Ser Pro  
275 280 285

Pro Ser Gln Gly Gly Pro Pro Arg Gly Arg Asp Trp Pro Ile Gly Gly  
290 295 300

Arg Gln Arg Gly Gly Ala Arg Pro Thr Ser Val Arg Arg Val Phe Gly  
305 310 315 320

Ala Arg Pro Ile Gly Arg Glu Leu Pro Pro Asn Gly Pro Gly Arg Pro  
325 330 335

Leu Pro Gly Met Val Ile Lys Asn Leu Gln Glu Ala Leu Phe Arg Phe  
340 345 350

Pro Val Trp  
355

- 48 -

2072627

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Asp Glu Tyr Asp Asp Ala Ala Asp Ala Ala Gly Asp Arg Ala Pro  
1                      5                      10                      15  
Gly Met

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 51 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CATGGACGAG TACGACGACC CAGCCGACGC CGCCGGCGAC CGGGCCCCCGG G

51

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 51 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 49 -

2072627

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CATGCCCCGGG GCCCGGTCGC CGGCGGCGTC GGCTGCGTCG TCGTACTCGT C

51

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GTTACGCTAG ACTAGTCTAG

20

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GTTACGCTAG ACTAGTCTAG

20

## WHAT IS CLAIMED IS:

1. A herpes simplex virus genome consisting essentially of an otherwise virulent herpes simplex virus genome rendered avirulent only by the lack of an ICP34.5 gene encoding an active gene product.

2. The herpes simplex virus genome as recited in claim 1 wherein said ICP34.5 gene comprises a stop codon in reading frame between a first and a last codon of a coding sequence of said ICP34.5 gene.

3. The herpes simplex virus genome as recited in claim 2 wherein said herpes simplex virus genome is an HSV-1 genome.

4. The herpes simplex virus genome as recited in claim 3 wherein said ICP34.5 gene comprises said stop codon at a BstEII restriction endonuclease site in the ICP34.5 gene of HSV-1(F).

5. The herpes simplex virus genome as recited in claim 2 wherein said herpes simplex virus genome is an HSV-2 genome.

6. The herpes simplex virus genome as recited in claim 1 wherein said ICP34.5 gene comprises a deletion mutation.

7. The herpes simplex virus genome as recited in claim 4 wherein said herpes simplex virus genome is a herpes HSV-1 genome and wherein said ICP34.5 gene lacks a portion of a coding sequence between BstEII and StuI restriction endonuclease sites in HSV-1(F).

- 51 -

2072627

8. The herpes simplex virus genome as recited in claim 6 wherein said portion is about 1000 base pairs in length.

5 9. The herpes simplex virus genome as recited in claim 6 wherein said herpes simplex virus genome is an HSV-1 genome.

10. The herpes simplex virus genome as recited in claim 6 wherein said herpes simplex virus genome is an HSV-2 genome.

10 11. A herpes simplex virus designated R3616 (ATCC VR2280).

12. A herpes simplex virus designated R4009 (ATCC VR2278).

15 13. A vaccine comprising a herpes simplex virus genome consisting essentially of a an otherwise virulent herpes simplex virus genome rendered avirulent only by the lack of an ICP34.5 gene encoding an active gene product, and a pharmaceutically acceptable diluent, adjuvant or carrier.

20 14. The vaccine as recited in claim 13 wherein said herpes simplex virus comprises an ICP34.5 gene having a stop codon in reading frame between a first and a last codon of a coding sequence of said ICP34.5 gene.

25 15. The vaccine as recited in claim 13 wherein said herpes simplex virus genome is an HSV-1 genome.

2072627

- 52 -

16. The vaccine as recited in claim 15 wherein said ICP34.5 gene comprises said stop codon at a BstEII restriction endonuclease site in the ICP34.5 gene of HSV-1(F).

5 17. The vaccine as recited in claim 14 wherein said herpes simplex virus genome is an HSV-2 genome.

18. The vaccine as recited in claim 13 wherein said herpes simplex virus comprises an ICP34.5 gene comprising a deletion mutation.

10 19. The vaccine as recited in claim 18 wherein said herpes simplex virus genome is an HSV-1 genome.

15 20. The vaccine as recited in claim 19 wherein said ICP34.5 gene lacks a portion of a coding sequence between BstEII and StuI restriction endonuclease sites in HSV-1(F).

21. The vaccine as recited in claim 19 wherein said portion is 1000 base pairs in length.

22. The vaccine as recited in claim 18 wherein said herpes simplex virus genome is an HSV-2 genome.

20 23. The vaccine as recited in claim 12 wherein said herpes simplex virus is a herpes simplex virus designated R3616 (ATCC VR2280).

25 24. The vaccine as recited in claim 13 wherein said herpes simplex virus is a herpes simplex virus designated R4009 (ATCC VR2278).

- 53 -

25. The use of a vaccine in immunity inducing dosage form for immunizing a human host against a herpes simplex virus wherein the vaccine comprises a herpes simplex virus genome consisting essentially of an otherwise virulent herpes simplex virus rendered avirulent only by the lack of an ICP34.5 gene encoding an active gene product and a pharmaceutically acceptable diluent, adjuvant or carrier.

26. The use according to claim 25 wherein said herpes simplex virus comprises an ICP34.5 gene having a stop codon in reading frame between a first and a last codon of a coding sequence of said ICP34.5 gene.

27. The use according to claim 26 wherein said herpes simplex virus genome is an HSV-1 genome.

28. The use according to claim 27 wherein said ICP34.5 gene comprises said stop codon at a BstEII restriction endonuclease site in the ICP34.5 gene of HSV-1(F).

29. The use according to claim 26 wherein said herpes simplex virus genome is an HSV-2 genome.

30. The use according to claim 25 wherein said herpes simplex virus comprises an ICP34.5 gene comprising deletion mutation.

31. The use according to claim 30 wherein said herpes simplex virus genome is an HSV-1 genome.

32. The use according to claim 31 wherein said ICP34.5 gene lacks a portion of a coding sequence between BstEII and StuI restriction endonuclease sites in HSV-1(F).

33. The use according to claim 31 wherein said portion is 1000 base pairs in length.

- 54 -

34. The use according to claim 30 wherein said herpes simplex virus genome is an HSV-2 genome.

35. The use according to claim 25 wherein said herpes simplex virus is a herpes simplex virus designated R3616 (ATCC VR2280).

36. The use according to claim 25 wherein said herpes simplex virus is a herpes simplex virus designated R4009 (ATCC VR2278).

37. A method for preparing a herpes simplex virus vaccine comprising the steps of:

preventing transcription of an active product from an ICP34.5 gene in an otherwise substantially intact herpes simplex virus; and

combining said vaccine virus with a pharmaceutically acceptable carrier.

38. The method as recited in claim 37 wherein said preventing step comprises the step of deleting a portion of said ICP34.5 gene.

39. The method as recited in claim 38 wherein said herpes simplex virus genome is an HSV-1 genome.

40. The method as recited in claim 39 wherein said deleting step comprises the step of removing a coding sequence between BstEII and StuI restriction endonuclease sites in HSV-1(F).

41. The method as recited in claim 39 wherein said removing step comprises taking out 1000 base pairs.

42. The method as recited in claim 38 wherein said herpes simplex virus genome is an HSV-2 genome.

- 55 -

43. The method as recited in claim 37 wherein said preventing step comprises the step of inserting a stop codon in reading frame between a first and a last codon of a coding sequence of said ICP34.5 gene.

44. The method for preparing a herpes simplex virus vaccine as recited in claim 43 wherein said inserting step comprises the step of introducing a stop codon at a BstEII restriction endonuclease site in the ICP34.5 gene of HSV-1(F).

45. The method as recited in claim 43 wherein said herpes simplex virus genome is an HSV-2 genome.

46. A recombinant herpes simplex virus genome having modified  $\gamma_1$ 34.5 genes incapable of expressing an active ICP34.5 gene product, wherein the modification is selected from the group consisting of insertions, substitutions and deletions wherein the deletions have at least one terminus within the  $\gamma_1$ 34.5 genes.

47. The herpes simplex virus genome of claim 46 wherein each said  $\gamma_1$ 34.5 gene comprises a stop codon in reading frame between a first and a last codon of a coding sequence of said  $\gamma_1$ 34.5 gene.

48. The herpes simplex virus genome of claim 47 wherein said virus is HSV-1(F) and at least one said  $\gamma_1$ 34.5 gene comprises said stop codon at a BstEII restriction endonuclease site therein.

49. The herpes simplex virus genome of claim 46 wherein at least one modified  $\gamma_1$ 34.5 gene comprises a deletion mutation.

50. The herpes simplex virus genome of claim 49 wherein said herpes simplex virus genome is HSV-1(F) and said deletion mutation comprises a portion of a coding sequence

- 56 -

between BstEII and StuI restriction endonuclease sites therein.

51. The herpes simplex virus genome of claim 46 wherein said virus is HSV-1.

52. The herpes simplex virus genome of claim 46 wherein said virus is HSV-2.

53. A vaccine comprising a herpes simplex virus genome having modified  $\gamma_1$ 34.5 genes incapable of expressing an active ICP34.5 gene product and a pharmaceutically acceptable diluent, adjuvant or carrier, wherein the modification is selected from the group consisting of insertions, substitutions and deletions wherein the deletions have at least one terminus within the  $\gamma_1$ 34.5 genes.

54. The vaccine of claim 53 wherein each said  $\gamma_1$ 34.5 gene comprises a stop codon in reading frame between a first and a last codon of a coding sequence of said  $\gamma_1$ 34.5 gene.

55. The vaccine of claim 49 wherein said virus is HSV-1(F) and at least one said  $\gamma_1$ 34.5 gene comprises said stop codon at a BstEII restriction endonuclease site therein.

56. The vaccine of claim 53 wherein at least one said  $\gamma_1$ 34.5 gene comprises a deletion mutation.

57. The vaccine of claim 56 wherein said virus is HSV-1(F) and said deletion mutation comprises a portion of a coding sequence between BstEII and StuI restriction endonuclease sites therein.

58. The vaccine of claim 53 wherein said virus is HSV-1.

59. The vaccine of claim 53 wherein said virus is HSV-2.

- 57 -

60. The use of vaccine in immunity inducing dosage form for immunizing a host against a herpes simplex virus wherein the vaccine comprises a herpes simplex virus genome having modified  $\gamma_1$ 34.5 genes incapable of expressing an active ICP34.5 gene product and a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the modification is selected from the group consisting of insertions, substitutions and deletions wherein the deletions have at least one terminus within the  $\gamma_1$ 34.5 genes.

61. The use according to claim 61 wherein each said  $\gamma_1$ 34.5 gene has a stop codon in reading frame between a first and a last codon of a coding sequence of said  $\gamma_1$ 34.5 gene.

62. The use according to claim 61 wherein said virus is HSV-1(F) and at least one said  $\gamma_1$ 34.5 gene comprises said stop codon at a BstEII restriction endonuclease site therein.

63. The use according to claim 60 wherein at least one modified  $\gamma_1$ 34.5 gene comprises a deletion mutation.

64. The use according to claim 63 wherein said virus is HSV-1(F) and said deletion mutation comprises a portion of a coding sequence between BstEII and StuI restriction endonuclease sites therein.

65. The use according to claim 60 wherein said virus is HSV-1.

66. The use according to claim 60 wherein said virus is HSV-2.

67. A method of preparing a vaccine comprising the steps of: modifying the  $\gamma_1$ 34.5 genes of a herpes simplex virus, to render said genes incapable of expressing an active ICP34.5 gene product and combining said virus with a pharmaceutically acceptable diluent, adjuvant, or carrier, wherein the

- 58 -

modification is selected from the group consisting of insertions, substitutions and deletions wherein the deletions have at least one terminus within the  $\gamma_1$ 34.5 genes.

68. The method of claim 67 wherein said modifying step comprises the step of inserting a stop codon in reading frame between a first and a last codon of a coding sequence of said  $\gamma_1$ 34.5 genes.

69. The method of claim 68 wherein said virus is HSV-1(F) and said inserting step comprises the step of introducing a stop codon at a BstEII restriction endonuclease site in the  $\gamma_1$ 34.5 genes thereof.

70. The method of claim 67 wherein said modifying step comprises the step of deleting a portion of said  $\gamma_1$ 34.5 genes.

71. The method of claim 71 wherein said virus is HSV-1(F) and said deleting step comprises the step of deleting a portion of a coding sequence between BstEII and StuI restriction endonuclease sites therein.

72. The method of claim 67 wherein said virus is HSV-1.

73. The method of claim 67 wherein said virus is HSV-2.

F:

17:

MGH:

CVG:

TTTAAAGTCG

CG

CAC

CGC

CGGCGGC

T

-A

-

--GCA

GG

GG

GG

DR1

CCCCGGGGCC

CCCCGGGGCC

CCCCGGGGCC

AGACGAGCGA

T

T

T

GT

TAGACAGG

60

F:

17:

MGH:

CVG:

CAAGCACTAC

TCGCCTCTGC

ACGCACATGC

TTGCCTGTCA

A

ACTCTACCA

CCCCGGCAGC

120

F:

17:

MGH:

CVG:

CTCTCTGTCT

CCATGGGCCG

CCGCGGCCGC

C---

ATCGGGCC

CCCCGGCCC

CCCCGGCCC

180

GCC

GCC

FIG. 1

2072627

INVENTOR  
BERNARD ROIZMAN

*Finlayson & Shinglebush*

PATENT AGENTS

2072627

F:

17:

MGH:

CVG:

GGGCCACGG GCGCGTCCC AACGACAG TCCAGGTAA CCTCCAGCC CAACTCGGAA

240

G  
G

F:

17:

MGH:

CVG:

CCCGCGGTCA GGAGCGCGCC CGCGCGCGCC CCGCGCGCC CCCCCGCCAG TGGCCCCCGG

300

T  
T

-----G  
G

F:

17:

MGH:

CVG:

CCTTCTTGTT CGCTGCTGCT GCGCCAGTGG CTCACGTT CCGAGTCCGC GTCCGACGAC

360

G  
G  
G  
G

FIG. 1 (cont'd)

INVENTOR  
BERNARD ROIZMAN

*Finlayson & Singelhurst*

PATENT AGENTS

420  
F: GACGATGACG ACGACTGGCC GGACAGCCCC CCGCCCGAGC CCGCGCCAGA GGCCCGGCCC  
17: T  
MGH:  
CVG:


480  
F: ACCGCCGCCG CCCCCCGCCC CC-GGTCCCC-A CCGCCCGCG CCGGCCCGG GGGCGGGCT  
17: C G C T  
MGH: - - - A  
CVG: - - -

540  
F: AACCCTCCC ACCCCCCCTC ACGCCCCCTC CGCTTCCG CCGCCTCGC CCTCCGCTG  
17: G G  
MGH:  
CVG: G

2072627

FIG. 1 (cont'd)

INVENTOR  
BERNARD ROIZMAN

  
PATENT AGENTS

2072627

F: CCGGTCACCG CAGAGCACCT GCGCGCCTG CGCCTGCGAC GCGCGGCGG GGAGGGGGCG 600  
17: G  
MGH: G  
CVG:

F: CCGGAGCCCC CCGGACCCC CCGACCCC GCGACCCC CGACCCCGC GACCCCGCG 660  
17: \* \* \* \* \*  
MGH: \* \* \* \* \*  
CVG: \* \* \* \* \*

F: ACCCGCGGA CCGCGGAC CCGCGACC CCGCGACCC CCGCGGGT GCGCTTCTCG 720  
17: \* \* \* \* \*  
MGH: \* \* \* \* \*  
CVG: \* \* \* \* \*

FIG. 1 (cont'd)

INVENTOR  
BERNARD ROIZMAN

*Finlayson & Shingelund*

PATENT AGENTS

2072627

780  
CCCCACGTCC GGGTGGCCA CCTGGTGGTC TGGCCTCGG CCGCCGCCCT GCGCGCCGC

F:  
17:  
MGH:  
CVG:

840  
GGCTCGTGGG CCGCGAGCG GCGGACCGG GCTCGGTTCC GCGCCGGGT GCGGAGGCC

F:  
17:  
MGH:  
CVG:

900  
GAGGCGGTCA TCGGCCGTG CCTGGGGCC GAGGCCGTG CCGGCCCT GCGCGCGGA

F:  
17:  
MGH:  
CVG:

C    A    C

FIG. 1 (cont'd)

INVENTOR  
BERNARD ROIZMAN

*Finlayson & Shingler*

PATENT AGENTS

2072627

960  
GCCGGCCCCG CGAACTCGGT CTAACGTTAC ACCGAGGCG GCTGGGTCT TCCGGGAGC

F:  
17:  
MGH:  
CVG:

1020  
TCCGGGAGC TCCGCACCAA GCCGCTCTCC GGAGAGACGA TGGAGGAGC CGGCATATA

A  
A  
F:  
17:  
MGH:  
CVG:

1080  
TACGCTGGGA GCCGGCCCGC CCC--GAGCG GGCCGCCCT CGGAGGGCG GACTGGCAA  
T A  
T ACAG

F:  
17:  
MGH:  
CVG:

FIG. 1 (cont'd)

INVENTOR  
BERNARD ROIZMAN

*Finlayson & Singelhurst*

PATENT AGENTS

1140

F: TCGGCGGCCG CCAGCGCGGC GGGGCCGGC CAACGAGCT CCGCGAGTC TTCGGGGCCC

17: G

MGH: G

CVG:

1200

F: GGCCCACTGG GCGGAGTTA CCGCCAGTG GGCGGGCGG CCCACTTCCC GGTATGGTAA

17: T A

MGH: T AC C

CVG: T AC C

1260

F: TTAAAACTT ACAAGAGGCC TTGTTCCGCT TCCGGTAGT GTAATTAGAA ACTCATTAAAT

17: G G G


MGH:

CVG:

2072627

FIG. 1 (cont'd)

INVENTOR  
BERNARD ROIZMAN

  
PATENT AGENTS

2072627

1320  
GGGGGGCCC GCGCGCCCTT CCGCTTCCG GCAATTCCG CGGCCCTTAA TGGGCAACCC

F:  
17:  
MGH:  
CVG:

1335  
CGGTATTCCC CGCCT

F:  
17:  
MGH:  
CVG:

FIG. 1 (cont'd)

INVENTOR  
BERNARD ROIZMAN

*Finlayson & Shinglehurst*

PATENT AGENTS

MET ALA ARG ARG ARG ARG --- HIS ARG GLY PRO ARG ARG PRO PRO GLY PRO THR GLY 20

ARG  
ARG

ALA VAL PRO THR ALA GLN SER GLN VAL THR SER THR PRO ASN SER GLU PRO ALA VAL ARG SER 41

VAL  
VAL

ALA PRO ALA ALA ALA PRO PRO PRO PRO ALA SER GLY PRO PRO SER CYS SER LEU LEU 62  
GLY  
-----GLY  
GLY

LEU ARG GLN TRP LEU HIS VAL PRO GLU SER ALA SER ASP ASP ASP ASP ASP TRP PRO 83

GLN

FIG. 2

2072627

INVENTOR  
BERNARD ROIZMAN

*Frederickson & Shingler*

PATENT AGENTS

ASP SER PRO PRO PRO GLU PRO ALA PRO GLU ALA ARG PRO THR ALA ALA PRO ARG PRO ARG  
SER  
104

SER PRO PRO PRO GLY ALA GLY PRO GLY GLY GLY GLY ALA ASN PRO SER HIS PRO PRO SER ARG PRO  
GLY PRO HIS ARG PRO ALA TRP ALA ARG GLY ALA GLY LEU THR PRO THR PRO PRO ARG ALA  
125

ASP

PHE ARG LEU PRO PRO ARG LEU ALA LEU ARG LEU ARG VAL THR ALA GLU HIS LEU ALA ARG LEU  
PRO SER ALA PHE ARG ARG ALA SER PRO SER ALA CYS ALA SER PRO ARG SER THR TRP ARG ALA  
146

ARG LEU ARG ARG ALA GLY GLY GLU GLY ALA PRO GLU PRO PRO ALA THR PRO ALA THR PRO ALA  
CYS ALA CYS ASP ALA ARG ALA GLY ARG GLY ARG ARG SER PRO PRO ARG PRO PRO PRO PRO  
LYS  
\* \*  
\*167

THR PRO ALA THR PRO ALA THR PRO ALA THR PRO ALA THR PRO ALA THR PRO ALA  
ARG PRO PRO ARG PRO PRO PRO ALA THR PRO ALA THR PRO ALA THR PRO ALA  
\* \* \* \* \*  
\*188

2072627

FIG. 2 (cont'd)

INVENTOR  
BERNARD ROIZMAN

*Frederick & Singletree*

PATENT AGENTS

THR PRO ALA ARG VAL ARG PHE SER PRO HIS VAL ARG VAL ARG HIS LEU VAL VAL TRP ALA SER  
--- --- PRO ARG GLY CYS ALA SER ARG PRO THR SER GLY CYS ALA THR TRP TRP SER GLY PRO 209

ALA ALA ARG LEU ALA ARG ARG GLY SER TRP ALA ARG GLU ARG ALA ASP ARG ALA ARG PHE ARG  
ARG PRO PRO ALA TRP ARG ALA ALA ARG GLY PRO ALA SER GLY PRO THR GLY LEU GLY SER 230

ARG ARG VAL ALA GLU ALA GLU ALA VAL ILE GLY PRO CYS LEU GLY PRO GLU ALA ARG ALA ARG  
GLY ALA GLY TRP ARG ARG PRO ARG ARG SER SER SER GLY ALA TRP GLY PRO ARG PRO VAL PRO 251

LYS

ALA LEU ALA ARG GLY ALA GLY PRO ALA ASN SER VAL OC 263  
GLY PRO TRP PRO ALA GLU PRO ALA ARG ARG THR ARG SER ASN VAL THR PRO GLU ALA ALA TRP  
VAL PHE ARG GLY ALA PRO GLY SER SER ALA PRO SER ARG SER PRO GLU ARG ARG TRP GLN GLU  
PRO ARG ILE TYR THR LEU GLY ALA SER PRO PRO SER GLN GLY GLY PRO PRO ARG GLY ARG ASP

2072627

FIG. 2 (cont'd)

INVENTOR  
BERNARD ROIZMAN

*Bernard Roizman*

PATENT AGENTS

2072627

TRP PRO ILE GLY GLY ARG GLN ARG GLY GLY GLY ALA ARG PRO THR SER VAL ARG ARG VAL PHE GLY  
ALA ARG PRO ILE GLY ARG GLU LEU PRO PRO ASN GLY PRO GLY ARG PRO LEU PRO GLY MET VAL  
ILE LYS ASN LEU GLN GLU ALA LEU PHE ARG PHE PRO VAL TRP OC


FIG. 2 (cont'd)


INVENTOR  
BERNARD ROIZMAN

*Finlayson & Shinglehurst*

PATENT AGENTS

# FIG. 3





|       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met   | Asp | Glu | Tyr | Asp | Asp | Ala | Ala | Ala | Ala | Gly | Asp | Arg | Ala | Pro | Gly | Met |
| .C    | ATG | GAC | GAG | TAC | GAC | GAC | GCA | GCC | GCC | GCC | GAC | CGG | GCC | CCG | GG  | GG  |
| ..... | CTG | CTC | ATG | CTG | CTG | CGT | CGG | CTG | CGG | CCG | CTG | GCC | CGG | GGC | CCG | TAC |

2072627

FIG. 3 (cont'd)

INVENTOR  
BERNARD ROIZMAN

*Stanley & Singel*  
PATENT AGENTS




Fig. 4

INVENTOR  
BERNARD ROIZMAN


*Frederickson & Singletree*

PATENT AGENTS

55

HSV-1(F)A305

R4002



Truncated  
 $\chi^2$  34.5

2072627


INVENTOR  
BERNARD ROIZMAN

*Farayan & Singhal*  
PATENT AGENTS

2072627


FIG. 5 (cont'd)

R3617  
(R3616)



$\gamma_1$  34.5 -


HSV-1(F)R



$\gamma_1$  34.5F +

F restored ICP 34.5

R4010  
(R4009)



$\gamma_1$  34.5 -  
(stop codon)

INVENTOR  
BERNARD ROIZMAN

*Frederickson & Shingler*

PATENT AGENTS






Fig. 6

INVENTOR  
BERNARD ROIZMAN

*Bernard Roizman*

PATENT AGENTS

2072627




Fig. 7

INVENTOR  
BERNARD ROIZMAN

*Farleyson & Singhal*

PATENT AGENTS